US Patent No: 4,472,382

Number of patents in Portfolio can not be more than 2000

Treatment method

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A novel method of treating prostate adenocarcinoma, prostate benign hypertrophia, endometriosis, dysmenorrhea, hirsuitism, hormono-dependent mammary tumors, treatment and prevention of precocious puberty, induction of a retardation of the appearance of puberty and treatment of acne of mammals comprising administering to warm-blooded animals an effective amount of a peptide of the formula p Glu--His--Trp--Ser--Tyr--X--Y--Arg--Pro--Z (I) wherein (a) Z is Gly--NH.sub.2, Y is Leu and X is Gly, (b) Z is Gly--NH.sub.2, Y is Leu, X is DN Leu, DN Val, D Abu (.alpha.-aminobutyric acid), D Phe, D Ser, D Thr, D Met, D Pgl, D Lys, Leu, Ile, Nle, Val, N Val, Met, Phe, D Leu, D Arg, D Ser (tbu), D Thr (tbu), D Cys (tbu), D Asp (O tbu), D Glu (Otbu), D Orn (boc), D Lys (boc), D Trp, Trp, 2-methyl Ala, D Tyr, D Met, .epsilon.-lauryl -D Lys, .epsilon.-dextran-D Lys, (c) Z is NH-cyclopropyl-or NH--Alk wherein Alk is alkyl of 1 to 3 carbon atoms, Y is Leu and X is D Ser (tbu), D Thr (tbu), D Asp (Otbu), D Glu (Otbu), D Orn (boc), D Lys (boc), (d) Z is --NH--CH.sub.3, --NH--CH.sub.2 --CH.sub.3, NH--CH.sub.2 --CH.sub.2 --CH.sub.3, --NH--CH.sub.2 --CH.sub.2 --OH, ##STR1## Y is Leu and X is Gly, (e) Z is --NH--CH.sub.2 --CH.sub.3, Y is Leu and X is D Trp, D Leu, D Ala, D Ser (tbu), D Tyr, D Lys, Ala, (f) Z is Gly--NH.sub.2 or --NH--CH.sub.2 --CH.sub.3, Y is N.alpha.Me Leu and X is Gly, (g) Z is --NH--cyclopropyl, Y is Leu and X is D Leu or (h) Z is Gly--NH.sub.2, --NH--cyclopropyl or --NHAlk' where Alk' is alkyl of 1 to 3 carbon atoms, Y is Ser (but), Cys (but), Asp (Obut), Glu (Obut), Orn (boc), Lys (boc) and X is Gly.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
AVENTIS PHARMA S.A.ANTONY835
SCHERING CORPORATIONKENILWORTH, NJ1104

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Labrie, Fernand Sainte-foy, CA 119 1231
Raynaud, Jean-Pierre Paris, FR 12 157

Cited Art

Patent Info (Count) # Cites Year
 
G. D. SEARLE & CO. (1)
4,234,571 Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone 57 1979
 
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (1)
4,244,946 Water-soluble peptides affecting gonadal function 60 1979

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
BIOCON LIMITED (28)
6,479,692 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof 3 2001
6,858,580 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same 20 2001
6,835,802 Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties 8 2001
6,828,297 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same 9 2001
6,828,305 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same 5 2001
6,713,452 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same 11 2001
6,913,903 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same 4 2001
7,060,675 Methods of treating diabetes mellitus 6 2002
6,867,183 Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith 9 2002
6,770,625 Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith 8 2002
6,812,362 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof 1 2002
7,713,932 Calcitonin drug-oligomer conjugates, and uses thereof 0 2002
7,608,584 Calcitonin drug-oligomer conjugates, and uses thereof 0 2002
7,196,059 Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith 3 2003
7,166,571 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same 2 2003
7,030,082 Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith 3 2003
7,312,192 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same 0 2003
7,601,688 Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus 1 2003
7,030,084 Drug-oligomer conjugates with polyethylene glycol components 9 2004
7,084,121 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same 0 2004
7,084,114 Mixtures of insulin drug-oligomer comprising polyalkylene glycol 7 2004
7,611,864 Proinsulin polypeptide-oligomer conjugates 0 2004
7,875,700 Cation complexes of insulin compound conjugates, formulation and uses thereof 0 2005
7,872,095 Insulin-oligomer conjugates, formulations and uses thereof 0 2005
7,423,014 Insulin conjugates for treating diabetes mellitus 0 2005
7,470,663 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same 0 2006
7,381,702 Methods of treating diabetes mellitus 0 2006
8,030,269 Calcitonin drug-oligomer conjugates, and uses thereof 0 2009
 
ENDORECHERCHE, INC. (22)
5,550,107 Combination therapy for the treatment of estrogen-sensitive disease 31 1991
5,204,337 Estrogen nucleus derivatives for use in inhibition of sex steroid activity 16 1992
5,372,996 Method of treatment of androgen-related diseases 40 1992
5,364,847 Inhibitors of sex steroid biosynthesis and methods for their production and use 24 1992
5,362,720 Methods of treating or preventing breast or endometrial cancer with low dose non-masculinizing androgenic compounds 48 1993
5,631,249 Estrogen nucleus derivatives for use in the inhibition of sex steroid activity 2 1993
5,593,981 Method and treatment of androgen-related diseases 10 1993
5,595,985 Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia 22 1993
5,494,914 Inhibitors for testosterone 5.alpha.-reductase activity 8 1994
5,545,634 Activation of androgen receptors with low dose non-masculinizing androgenic compounds 15 1994
5,585,405 Inhibitors of sex steroid biosynthesis and methods for their production and use 1 1994
5,840,735 Sex steroid activity inhibitors 19 1994
6,060,503 Benzopyran-containing compounds and method for their use 4 1995
5,629,303 Controlled release systems and low dose androgens 16 1995
6,423,698 Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia 1 1995
5,861,387 Controlled release systems and low dose androgens 52 1995
5,846,960 Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds 26 1995
5,817,649 Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia 14 1995
5,814,340 Controlled release systems and low dose androgens 5 1995
5,686,465 Sex steroid activity inhibitors 12 1995
5,610,150 Method of treatment of androgen-related diseases 8 1995
5,567,695 Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds 21 1995
 
BRISTOL-MYERS SQUIBB COMPANY (10)
6,960,474 Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator 19 2001
6,953,679 Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof 10 2001
7,470,797 Fused heterocyclic imido and amido compounds 0 2004
7,141,578 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function 4 2004
7,291,637 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function 0 2005
7,432,267 Fused cyclic modulators of nuclear hormone receptor function 1 2005
7,517,904 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function 0 2005
7,342,034 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function 0 2005
7,655,688 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function 0 2005
7,655,689 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function 0 2006
 
AVENTIS PHARMA S.A. (5)
4,728,640 Treatment of dysmenorrhea 13 1986
4,745,102 Novel treatment method 9 1986
4,851,386 Method of treating precocious puberty 8 1987
5,189,021 Method of treating precocious puberty 6 1990
5,712,251 Treatment method 1 1995
 
BAXTER INTERNATIONAL INC. (3)
6,090,925 Macromolecular microparticles and methods of production and use 79 1996
5,981,719 Macromolecular microparticles and methods of production and use 68 1998
6,268,053 Macromolecular microparticles and methods of production and use 68 2000
 
G. D. SEARLE & CO. (3)
6,858,598 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia 1 2001
6,833,373 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia 3 2001
6,689,787 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia 1 2001
 
SCHERING CORPORATION (2)
4,895,715 Method of treating gynecomastia 9 1989
5,389,613 Method of treating prostate adenocarcinoma, prostate benign hypertrophia and endometriosis 8 1993
 
ENDORECHERCHE, A CANADIAN CORPORATION (1)
5,395,842 Anti-estrogenic compounds and compositions 109 1991
 
HOECHST AKTIENGESELLSCHAFT (1)
5,091,367 Analogs of gonadoliberin with improved solubility, methods for their preparation, agents containing them and their use 3 1991
 
HOECHST MARION ROUSSEL (1)
4,743,589 Treatment of endometriosis 12 1984
 
INSTITUT FRANCAIS DU PETROLE (1)
7,605,123 Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof 1 2005
 
PAR PHARMACEUTICAL, INC. (1)
6,187,345 Flutamide compositions and preparations 0 1998
 
PHARMACIA CORPORATION (1)
6,649,645 Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia 1 1999
 
PROTEIN DELIVERY INC. (1)
7,169,889 Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin 1 2000
 
RICHTER GEDEON VEGYESZETI GYAR RT. (1)
4,948,873 Gonadoliberine analogues of high activity 0 1986
 
ROUSSEL UCLAF (1)
4,981,842 Method of treating hormonal dependent mammary tumors in female mammals 4 1989
 
SUGEN, INC. (1)
6,482,848 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives 8 2001
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
7,001,911 Fused cyclic modulators of nuclear hormone receptor function 9 2002
 
UCLAF; ROUSSEL (1)
5,688,769 Treatment method 1 1994
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (5)
4,775,660 Treatment of breast cancer by combination therapy 38 1984
4,666,885 Combination therapy for treatment of female breast cancer 25 1985
4,760,053 Combination therapy for selected sex steroid dependent cancers 58 1986
5,068,221 Treatment of motility disorders with a GnRH analog 4 1989
5,434,136 Treatment of motility disorders with a GNRH analog 2 1992